KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Current Leases (2019 - 2025)

Fulgent Genetics' Current Leases history spans 7 years, with the latest figure at $1.3 million for Q1 2025.

  • For Q1 2025, Current Leases fell 54.3% year-over-year to $1.3 million; the TTM value through Mar 2025 reached $1.3 million, down 54.3%, while the annual FY2024 figure was $1.4 million, 63.53% down from the prior year.
  • Current Leases for Q1 2025 was $1.3 million at Fulgent Genetics, down from $1.4 million in the prior quarter.
  • Across five years, Current Leases topped out at $6.1 million in Q4 2022 and bottomed at $1.0 million in Q2 2021.
  • The 5-year median for Current Leases is $1.5 million (2024), against an average of $2.6 million.
  • The largest annual shift saw Current Leases surged 99.8% in 2021 before it tumbled 63.53% in 2024.
  • A 5-year view of Current Leases shows it stood at $1.0 million in 2021, then skyrocketed by 512.59% to $6.1 million in 2022, then crashed by 35.47% to $4.0 million in 2023, then crashed by 63.53% to $1.4 million in 2024, then dropped by 7.83% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Current Leases are $1.3 million (Q1 2025), $1.4 million (Q4 2024), and $1.5 million (Q3 2024).